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An Update on Cardioprotection
A Review of the Latest Adjunctive Therapies to
Limit Myocardial Infarction Size in Clinical Trials
Paul Z. Gerczuk, MD,* Robert A. Kloner, MD, PHD*†
Los Angeles, California
Acute myocardial infarction (AMI) with subsequent left ventricular dysfunction and heart failure continues to be
a major cause of morbidity and mortality in the Western world. Rapid advances in the treatment of AMI, mainly
through timely reperfusion, have substantially improved outcomes in patients presenting with acute coronary
syndrome and particularly ST-segment elevation myocardial infarction. A vast amount of research, both transla-
tional and clinical, has been published on various pharmacological and interventional techniques to prevent
myocardial cell death during the time of ischemia and subsequent reperfusion. Several methods of cardioprotec-
tion have shown the ability to limit myocardial infarction size in clinical trials. Examples of interventional tech-
niques that have proven beneficial are ischemic post-conditioning and remote ischemic per-conditioning, both of
which can reduce infarction size. Lowering core body temperature with cold saline infusion and cooling catheters
have also been shown to be effective in certain circumstances. The most promising pharmaceutical cardiopro-
tective agents at this time appear to be adenosine, atrial natriuretic peptide, and cyclosporine, with other poten-
tially effective medications in the pipeline. Additional pre-clinical and clinical research is needed to further investi-
gate newer cardioprotective strategies to continue the current trend of improving outcomes following AMI.
(J Am Coll Cardiol 2012;59:969–78) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.054Acute myocardial infarction (AMI) remains the leading cause
of death in the United States, with nearly 1 million AMIs
occurring annually, approximately 29% of which are ST-
segment elevation myocardial infarctions (STEMIs) (1). Ad-
vances in our understanding of the pathogenesis of coronary
artery occlusion and myocardial necrosis have led to dramatic
improvements in morbidity and mortality following AMI. By
1986 (2), re-establishing flow in the occluded coronary artery
y intravenous thrombolytic therapy was the standard of care
or both reducing the incidence of subsequent heart failure and
ecreasing mortality (3,4). The theory of salvaging myocar-
ium that would otherwise be condemned to ischemic death by
estoring blood flow proved to be viable, and better techniques
f opening the occluded coronary artery were quickly devel-
ped. Percutaneous transluminal coronary angioplasty (5–7),
nd coronary stenting (8–11) were extensively studied during
he 1990s, and by 2000, they were considered, when available,
he preferred strategy over thrombolytics (12,13). Over the last
ecade, many adjuvant medications (primarily antiplatelet
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accepted July 19, 2011.drugs to keep the artery open) have been shown to be beneficial
in the setting of AMI with mechanical reperfusion (14–16).
Although decreases in delays to establish coronary reperfu-
sion and medications to maintain coronary patency have led to
better outcomes following AMI, further improvements in
morbidity and mortality from refinement of these techniques
are likely to be small. Since the 1980s, an extraordinary amount
of research has been conducted to find an agent that would
render myocardial cells more resistant to the deleterious effects
of ischemia followed by reperfusion. This idea of cardioprotec-
tion encompasses manipulation of the cellular events by phar-
macotherapy or other therapies during ischemia and reperfu-
sion to reduce the amount of myocardial cell death. This differs
from the current (and well-proven) strategy of minimizing the
time that the myocardium is ischemic by re-establishing blood
flow as soon as possible. Although many potential cardioprotective
agents have floundered in clinical trials over the years (Table 1)
(17), a better understanding of the cellular mechanisms behind
ischemia-reperfusion injury has led to improved results in recent
clinical trials of several new cardioprotective drugs and interven-
tions. The following review attempts to bring to light some
promising new adjunctive therapies for reperfusion-treated AMI.
Ischemic Conditioning and Drugs
That Mimic Its Effect
Pre-conditioning. Activating the body’s endogenous pro-
tective mechanisms through repeated nonlethal bouts of
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prolonged episode of ischemia is
a powerful way to limit infarct
size. This technique, known as isch-
emic pre-conditioning, was de-
scribed 25 years ago by Murry et al.
(18), and it continues to be the gold
standard against which all experi-
mental cardioprotective agents are
judged. By definition, ischemic pre-
conditioning must be applied before
the ischemic event, making it diffi-
cult to use in the setting of AMI. It
is, however, effective in cardiac sur-
gery (19) and elective percutaneous
coronary intervention (PCI) (situa-
tions in which myocardial ischemia
is planned) (20).
Perhaps even more valuable, the study of pre-
conditioning has led to improved understanding of the
mechanisms of ischemia-reperfusion injury, which has
opened the door for pharmacological agents that can mimic
the effect of ischemic conditioning. The physiological,
cellular, and molecular mechanisms of ischemic pre-
conditioning have been studied for many years, and a
detailed discussion is beyond the scope of this review.
Briefly, the short episodes of ischemia-reperfusion recruit
cell surface receptors to various autocoids (e.g., adenosine,
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
ANP  atrial natriuretic
peptide
LV  left ventricular
MI  myocardial infarction
MPTP  mitochondrial
permeability transition pore
PCI  percutaneous
coronary intervention
PDE5  phosphodiesterase-5
STEMI  ST-segment
elevation myocardial
infarction
Recent Cardioprotection Trials That Failed to Show a Reduction inTable 1 Recent Cardioprotection Trials That Failed to Show a R
Therapeutic Agent Trial Design (Ref. #)
LeukoArrest
CD11/CD18 leukocyte integrin
receptor inhibitor
HALT-MI (96)
420 patients randomized to LeukoArrest 0.3 m
LeukoArrest 1.0 mg/kg, or placebo before re
Eniporide
Na/H exchange inhibitor
ESCAMI (97)
959 patients randomized to 10-min infusion of
eniporide 150 mg, or placebo before reperfu
Caldaret
Intracellular Ca2-handling
modulator
CASTEMI (98)
387 patients randomized to a 48-h infusion of c
caldaret 172.5 mg, or placebo initiated befo
Nicorandil
K channel opener/vasodilator
J-WIND-KATP (58)
545 patients randomized to 0.067-mg/kg bolus
24-h infusion of 1.67 g/kg/min of nicorand
GIK
glucose-insulin-potassium
CREATE-ECLA (99)
20,201 patients randomized to usual care plus
GIK or usual care alone
Delcasertib
-protein kinase C inhibitor
PROTECTION-AMI (100)
Anterior MI cohort: 1,010 patients randomized
delcasertib 50 mg/h, 150 mg/h, 450 mg/h,
before PCI
Inferior MI cohort: 166 patients randomized to
delcasertib 450 mg/h or placebo initiated be
Erythropoietin REVEAL (101)
222 patients randomized to intravenous epoeti
within 4 h of reperfusionCK-MB  creatine kinase-MB; GIK  glucose-insulin-potassium; LVEF  left ventricular ejection fraction;
intervention; SPECT  single-photon emission computed tomography.bradykinin, opioids) that are released during ischemia.
These receptors initiate a complex signaling cascade involv-
ing many protective kinases, including the reperfusion injury
salvage kinase group, reactive oxygen species, and mito-
chondrial components (all targets for pharmacotherapy).
The end result is a cardioprotective state that is mediated by
several effector molecules, such as the mitochondrial per-
meability transition pore (MPTP) (21) and others. The
reader is referred to several fine reviews on the mechanisms
of cardioprotection and conditioning (21–23).
Additionally, other methods of ischemic conditioning
that are more clinically applicable have been developed and
have proven to reduce myocardial infarct size both in animal
models and in clinical studies.
Post-conditioning and cyclosporine. Although ischemic
pre-conditioning has consistently proven to be cardiopro-
tective, its clinical application is clearly limited. In hopes of
making ischemic conditioning clinically relevant, Zhao et al.
(24) used the principles of ischemic pre-conditioning but
applied them after the ischemic event took place (closely
mimicking the setting of an AMI) in a canine model of
myocardial ischemia-reperfusion. Indeed, these brief epi-
sodes of coronary artery occlusion applied immediately after
the ischemic insult limited the MI size in the same manner
as ischemic pre-conditioning.
Although not all animal models have consistently shown
a benefit of post-conditioning on infarct size, there are
compelling data in humans. Within 2 years of the initial
ct Sizetion in Infarct Size
Year Outcome
ion
2002 No difference in infarct size measured by SPECT
No improvement in clinical events
ide 100 mg,
2001 No difference in infarct size measured by mean
release of -hydroxybutyrate dehydrogenase
No improvement in clinical outcomes
t 57.5 mg,
rfusion
2006 No difference in infarct size measured by SPECT
No difference in LVEF on day 7 or 30
ed by
lacebo
2007 No difference in infarct size measured by CK-MB
release
nfusion of
2005 No difference in mortality, cardiac arrest,
cardiogenic shock, reinfarction, or heart failure
h infusion of
cebo initiated
nfusion of
CI
2011 No difference in infarct size measured by CK-MB
release or ST-segment resolution in either
cohort
No difference in clinical outcomes
r placebo
2011 No difference in infarct size as measured by
cardiac MRI at 2 to 6 days or 12 2 weeks
Increased infarct size in patients 70 yrs who
received epoetin-alfa
Increased incidence of composite outcome of
death, MI, stroke, or stent thrombosis in
epoetin-alfa groupInfareduc
g/kg,
perfus
enipor
sion
aldare
re repe
follow
il or p
24-h i
to 2.5-
or pla
2.5-h i
fore P
n-alfa oMI  myocardial infarction; MRI  magnetic resonance imaging; PCI  percutaneous coronary
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tioning was already being investigated clinically (Table 2).
In 2005, Staat et al. (25) published a landmark study of
post-conditioning. This was a multicenter randomized con-
trolled trial of 30 patients with STEMI involving the left
anterior descending coronary artery or the right coronary
artery that was undergoing PCI. Their protocol of post-
conditioning consisted of 4 cycles of 1-min balloon inflation
followed by 1 min of balloon deflation within 1 min of
reflow after deployment of a coronary stent. Patients in the
post-conditioning group were found to have 36% smaller
infarctions as determined by serum creatine kinase (CK)
release during the first 72 h of reperfusion and lower peak
CK levels. The blush grade was also significantly higher in
the post-conditioning group than controls, likely represent-
ing improved myocardial perfusion in the first minutes
following reperfusion.
In 2008, Laskey et al. (26) used a protocol of 2 cycles of
90 s of balloon inflation followed by 3 min of reperfusion in
patients presenting within 6 h of a transmural anterior wall
AMI. They found that post-conditioned patients had sig-
nificantly lower peak CK levels, greater and more rapid
ST-segment resolution, and improved distal coronary flow
velocity parameters.
Clinical Trials Examining Post-Conditioning in Acute STEMITable 2 Clinical Trials Examining Post-Conditioning in Acute ST
First Author, Year
(Ref. #) Study Design Post-Conditi
Staat et al., 2005 (25) Prospective, open-label multicenter
randomized controlled study
(N  30)
4 cycles of 1-min
reperfusion w
index reperfus
Laskey 2005 (102) Prospective, open-label single-center
randomized controlled study
(N  17)
2 cycles of 90-s
3–5-min repe
Laskey et al., 2008 (26) Prospective, open-label single-center
randomized controlled study
(N  24 patients with anterior
STEMI)
2 cycles of 90-s
3-min reperfu
Ma et al., 2006 (103) Prospective, open-label single-center,
randomized controlled study
(N  94 patients with first STEMI)
3 cycles of 30-s
30-s reperfusi
1 min of inde
Thibault et al., 2008
(104)
Prospective, open-label single-center
randomized controlled study
(N  38 patients with first STEMI)
4 cycles of 1-min
1-min reperfu
1 min of inde
Lonborg et al., 2010
(105)
Prospective, open-label single-center
randomized controlled study
(N  118)
4 cycles of 30-s
30-s reperfusi
1 min of indeCK creatine kinase; CK-MB creatine kinase-MB; CTFC corrected thrombolysis in myocardial infarctio
computed tomography; MRI  magnetic resonance imaging; STEMI  ST-elevation myocardial infarctionDespite subtle differences in post-conditioning protocols
including measurement of risk zone by Staat et al. (25–27),
both Laskey and Staat demonstrated cardioprotective effects
of post-conditioning.
These small clinical trials of ischemic post-conditioning
are promising and show the potential of post-conditioning
to improve both early markers of infarct size and myocardial
function up to 1 year after infarction (Table 2). A major
limitation of ischemic post-conditioning, however, is that it
can only be performed in the catheterization laboratory
during PCI. Although the benefits of primary PCI are well
established, many patients still receive thrombolytic therapy
as a method of reperfusion. A pharmacological agent that
mimics the effects of post-conditioning could be adminis-
tered to patients at the time of reperfusion, regardless of the
modality being used.
To date, cyclosporine is the most promising pharmaco-
logical post-conditioning mimetic. Cyclosporine is thought
to derive its cardioprotective effects from inhibiting forma-
tion of the MPTP, a key component of lethal reperfusion
injury (28). The MPTP appears to form in the early stages
of reperfusion in response to the calcium overload and
reactive oxygen species generation that develops with re-
perfusion (29). This large-diameter pore forms in the
Protocol Primary Endpoints Results
sion/1-min
min of
Serum CK release during first
72 h of reperfusion
Peak serum CK level
Blush grade during reflow
ST-segment shifts at 48 h
36% decrease in area under
the curve of CK release
Increased blush grade
ion/ Doppler-derived distal coronary
flow velocity parameters
ST-segment shift
Decreased magnitude of final
ST-segment elevation
Increased rate of ST-segment
resolution
Improved coronary flow
velocity reserve
ion/ Doppler-derived distal coronary
flow velocity parameters
ST-segment shift
Peak CK release
Greater and more rapid
ST-segment resolution
Improved coronary flow
velocity reserve
Lower peak serum CK level
ion/
hin
fusion
Serum CK/CK-MB release during
first 72 h
Myocardial contractile function
8 weeks after infarction
Corrected TIMI frame count
Level of oxidative stress
(MDA levels)
Faster CTFC
Greater change in WMSI
Lower peak CK-MB level
Lower MDA-reactive products
sion/
ithin
fusion
Infarct size (by CK and troponin)
SPECT rest-redistribution index at
6 months
Echocardiography at 1 yr
39% decrease in SPECT
rest-redistribution index
40% reduction in infarct size
Improved EF at 1 yr
Improved WMSI at 1 yr
ion/
hin
fusion
Myocardial salvage at 3 months as
assessed by delayed
enhancement cardiac MRI
19% reduction in infarct size
31% increase in salvage ratioEMI
oning
occlu
ithin 1
ion
occlus
rfusion
occlus
sion
occlus
on wit
x reper
occlu
sion w
x reper
occlus
on wit
x repern frame count; EF ejection fraction; MDAmalondialdehyde; SPECT single-photon emission
; WMSI  wall motion severity score index.
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molecules 1.5 kDa into the mitochondrial matrix, causing
osmotic swelling, damage, and/or destruction of the mito-
chondria. Additionally, the inner membrane becomes freely
permeable to protons, effectively uncoupling oxidative phos-
phorylation and disrupting ATP production (30). There is a
large body of evidence in multiple animal models suggesting
that, through inhibition of MPTP formation, cyclosporine
can significantly reduce infarct size when given at the time
of reperfusion (28,29). Interestingly, some of the cardiopro-
tective effects seen in both pre- and post-conditioning are
due to inhibition of MPTP formation, suggesting a com-
mon pathway linking these forms of protection (31).
In a small proof-of-concept clinical trial, Piot et al. (32)
demonstrated that cyclosporine administered at the time of
PCI could reduce the size of MI compared with placebo.
Fifty-eight patients presenting with acute STEMI were
randomized to receive either an intravenous bolus of cyclo-
sporine 2.5 mg/kg of body weight or normal saline. Infarct
size, as measured by CK release after reperfusion, was
reduced by 40% in the cyclosporine group (p  0.04)
compared with the control group (138,053 arbitrary units
[interquartile range (IQR): 114,008 to 283,461] for the
cyclosporine group vs. 247,930 arbitrary units [IQR:
145,639 to 404,349] for the control group). The median
area under the curve for troponin I release showed a trend
toward being lower in the cyclosporine group but was not
statistically significant. In a subgroup of 27 patients, cardiac
magnetic resonance imaging (MRI) was performed at 5 days
and 6 months after infarction. Patients in the cyclosporine
group had a significantly smaller area of hyperenhancement
than patients in the control group at 5 days (37 g [IQR: 21
to 51 g] for the treated patients vs. 46 g [IQR: 20 g to 65
g] for the controls; p  0.04). In a subsequent published
report, the same group related that the significant difference
in infarct size as measured by cardiac MRI persisted 6
months later (29  15 g in the cyclosporine group vs. 38 
14 g in the control group; p  0.04) (33). Currently, a large
multicenter trial involving approximately 1,000 patients is
underway to further investigate cyclosporine as a cardiopro-
tective agent.
Remote ischemic conditioning. There is accumulating
evidence that ischemic conditioning can limit myocardial
infarct size even when applied to a distant organ’s vascular
bed. This technique, known as “remote ischemic condition-
ing,” has been shown to be cardioprotective in various
animal models when administered before the ischemic event
(remote pre-conditioning) (34,35), after the ischemic event
(remote post-conditioning) (36,37), and during the ischemic
event (remote per-conditioning) (38). Practically, remote
conditioning is very attractive because even limb ischemia
induced by inflation of a blood pressure cuff can reduce
myocardial ischemic injury (38). Mechanistically, it appears
that remote conditioning activates similar signaling path-
ways as pre- and post-conditioning; however, it is unknown
how the conditioning stimulus applied to a remote organ isable to protect the heart. A current theory involves an
unknown humoral substance that is released from the
conditioned organ and exerts its effect on the heart (39,40).
Alternatively, a signal may be carried from afferent neurons
in the conditioned organ to efferent neurons terminating in
the heart (41). Further research is underway to clarify the
underlying mechanism.
In a recent study by Botker et al. (42), 333 patients with
acute STEMI were randomized to receive either PCI alone
or remote ischemic conditioning before PCI. The remote
per-conditioning began in an ambulance en route to the
hospital and consisted of intermittent arm ischemia through
4 cycles of alternating 5-min inflation to 200 mm Hg and
5-min deflation of a standard upper-arm blood pressure cuff.
The primary endpoint of this study was myocardial salvage
index 30 days after PCI as measured by gated single-photon
emission computed tomography. The researchers found a
significant improvement in myocardial salvage index in the
per-conditioning group as compared with controls (0.69 
0.27 for treated patients vs. 0.57  0.26 for controls; p 
0.03). There was also a trend, although not statistically
significant, toward smaller final infarct size in the per-
conditioning group (8 10% vs. 12 13%; p 0.10). This
study adds to the growing body of evidence that suggests
that ischemic conditioning is both feasible and effective in
real-world clinical situations. In addition, this specific tech-
nique of using upper-extremity limb ischemia en route to
the hospital is particularly exciting because of its conve-
nience and effectiveness. Larger clinical trials are underway
to refine this novel technique of cardioprotection.
Adenosine: AMISTAD I and II and Beyond
As the understanding of ischemic conditioning grew, it
became apparent that adenosine plays a central role in
triggering this pre-conditioned cardioprotective state
(43,44). Many different adenosine receptors and receptor
subtypes are expressed in cardiomyocytes, and their exact
role in the different methods of cardioprotection is not
completely understood. However, it is known that A1 and
A3 receptors, when engaged by adenosine or adenosine
agonists before lethal ischemia, trigger the pre-conditioned
state (43,44). The molecular signaling cascade by which this
occurs is complex and beyond the scope of this review (45);
however, the common final pathway again appears to be
inhibition of MPTP formation.
Although adenosine was clearly shown to be cardiopro-
tective when administered before lethal ischemia, its ability
to reduce infarct size in experimental models when admin-
istered during ischemia before reperfusion is somewhat
more controversial (46–50). Despite mixed results in vari-
ous animal models of ischemia-reperfusion, large-scale clin-
ical trials were undertaken to examine the role of adenosine
administered during evolving acute STEMI.
AMISTAD I (Acute Myocardial Infarction Study of
Adenosine) was the first large-scale clinical trial testing
973JACC Vol. 59, No. 11, 2012 Gerczuk and Kloner
March 13, 2012:969–78 Update on Cardioprotectionadenosine as an adjunct to reperfusion therapy (51). Pub-
lished in 1999, this multicenter randomized placebo-
controlled trial of 236 patients with STEMI treated with
thrombolytic therapy showed that adenosine infusion
caused a 33% relative reduction in infarct size. However,
this benefit was only observed in patients who suffered an
anterior MI, and in fact, patients with nonanterior infarc-
tions who received adenosine showed a trend toward in-
creased adverse clinical events.
AMISTAD II was designed to examine the effect of
adenosine as an adjunct therapy for patients with acute anterior
STEMI undergoing either thrombolysis or PCI (52). In this
trial, 2,118 patients were randomized to receive a 3-h intrave-
nous infusion of low-dose adenosine (50 g/kg/min), high-
dose adenosine (70 g/kg/min), or placebo before PCI or
within 15 min of the initiation of fibrinolysis. No difference in
the primary clinical composite endpoint of death, new-onset
congestive heart failure, or rehospitalization for congestive
heart failure within 6 months was observed between the
high-dose adenosine group, low-dose adenosine group, or
pooled adenosine dose group and placebo. The high-dose
adenosine group, however, did show a significant reduction in
infarct size compared with the control group (11% in the
treated group vs. 27% in the controls; p  0.023). These
findings confirmed the infarct size–reducing effects of high-
dose adenosine observed in AMISTAD I. A subsequent post
hoc analysis of AMISTAD II by Kloner et al. (53) showed
significant improvement in mortality and event-free survival in
a subset of patients who received adenosine and reperfusion
therapy within 3.17 h of symptom onset, and this population of
patients should be studied further in a randomized clinical trial
(54). Patients reperfused late (i.e., beyond 3.17 h of symptom
onset) did not demonstrate any clinical benefit of adenosine.
Intracoronary administration of adenosine has been stud-
ied in several clinical trials, with mixed results (55,56).
Recently, a randomized controlled study of 112 patients
presenting within 12 h of STEMI demonstrated no bene-
ficial effect of a 4-mg intracoronary bolus of adenosine
immediately before reperfusion (57). There was no signifi-
cant difference in the primary endpoint of myocardial
salvage index as measured by MRI between the 2 groups
(41.3% [IQR: 20.8% to 66.7%] for the treated group vs.
47.8% [IQR: 39.8% to 60.9%] for controls; p  0.52). A
major limitation of this study, however, was that adenosine
was administered as an intracoronary bolus. The half-life of
adenosine is only several seconds, making a bolus injection
unlikely to be effective. Intravenous/intracoronary infusion
of the drug allows it to remain in circulation longer, perhaps
allowing adequate time to be beneficial.
J-WIND Atrial Natriuretic Peptide
The J-WIND (Japan-Working Groups of Acute Myocardial
Infarction for the Reduction of Necrotic Damage) trial was 2
independent clinical trials that examined the effects of atrialnatriuretic peptide (ANP) and nicorandil on myocardial infarct
size, cardiac function, and clinical outcomes (58).
In J-WIND-KATP, 545 patients were randomized to
receive either nicorandil by bolus injection of 0.067 mg/kg
followed by an intravenous infusion of 1.67 g/kg/min for
24 h or saline infusion by the same method. No differences
in infarct size, chronic LV function, or cardiac events were
seen.
J-WIND-ANP was a multicenter randomized placebo-
controlled trial involving 27 hospitals. A total of 277
patients were randomized to receive a continuous infusion
of ANP for 3 days following reperfusion by either PCI or
thrombolytic therapy, and 292 patients were randomized to
receive placebo infusion (5% glucose) for the same time
period. The researchers showed that ANP, given acutely,
reduced total CK release (66,459.9 IU/ml per h in the
treated group vs. 77,878.9 IU/ml per h in controls), which
corresponded to a 14.7% reduction in infarct size. Patients
in the ANP group also had significantly less reperfusion
injury and a small but significant increase in ejection fraction
at 6 to 12 months compared with controls (44.7% vs.
42.5%). Finally, ANP significantly decreased cardiac death
and hospitalization due to heart failure over a median
follow-up time of 2.7 years.
Beta-Blockade
Cardioselective beta-blockers have an important and well-
established role in the treatment of AMI. The beneficial
effects of beta-blockers on LV remodeling, reinfarction,
life-threatening arrhythmias, and most importantly, mortal-
ity are well documented in published reports (59,60).
However, their effect on infarct size per se is somewhat
more controversial. Pre-clinical data on the infarct-sparing
effects of beta-blockers are mixed, and the majority of large
clinical trials that looked at the usefulness of beta-blockade in
AMI was carried out in the “pre-thrombolytic era.” The
consensus from these early trials was that beta-blockade might
reduce infarct size when given very early after the onset of
symptoms (4 to 7 h) (60–63).
Contemporary data on the cardioprotective effects of
beta-blockers are certainly sparse; however, the lack of data
provides an opportunity to discuss the process by which
potentially cardioprotective therapies should be investi-
gated. Over the last 25 years, there has been an obvious
disconnect between the promising results seen in pre-
clinical cardioprotection studies and clinical success (17,64)
(Table 1). There are many reasons for this; however, the
undertaking of premature clinical trials before adequate
pre-clinical research has been completed appears to be a
significant problem. Recently, the multicenter CAESAR
(Consortium for Preclinical Assessment of Cardioprotective
Therapies) initiative was supported by the National Heart
Lung and Blood Institute (54). This initiative was devel-
oped from a 2003 National Heart Lung and Blood Institute
working group that was convened to discuss methods to
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tice. CAESAR was created to more systematically examine
potential therapies in multiple laboratories and in different
animal models using a centralized core laboratory for assess-
ment of infarct size. This standardized approach, more
closely resembling a multicenter clinical trial, will hopefully
yield more accurate, reliable results before a therapy is tested
in clinical trials.
Although there is excitement about the cardioprotective
potential of new beta-blockers such as nebivolol (65,66),
sufficient pre-clinical investigation, including reproducible
results in multiple animal models, should be completed
before large-scale clinical testing.
Therapies That Show Promise
Under the Right Circumstances
Mild hypothermia. Therapeutic hypothermia is a well-
tudied method of protecting the ischemic heart from
nfarction. Multiple animal models have demonstrated the
ardioprotective effect of hypothermia, from mild hypother-
ia (32°C to 35°C) to moderate (28°C to 32°C), severe
20°C to 28°C), and profound (20°C) hypothermia (67–
1). Although the mechanism of protection in moderate
nd severe hypothermia appears to involve metabolic slow-
ng, mild hypothermia likely involves alterations in signaling
athways (67,72). Interestingly, Yang et al. (73) recently
ublished a study that suggested that preservation of extra-
ellular signal–regulated kinase activity by mild hypother-
ia contributed to a reduction in infarct size in rabbits (73).
xtracellular signal–regulated kinase is a member of the
eperfusion injury salvage kinases group of protective ki-
ases, which are involved in protection from ischemia-
eperfusion injury and have been shown to be activated in
ther methods of cardioprotection such as ischemic
onditioning.
Several early clinical trials attempted to translate this
enefit to humans, with limited success (74); however,
ypothermia can indeed limit infarct size under certain
onditions. COOL-MI (Cooling as an Adjunctive Therapy
o Percutaneous Intervention in Patients With Acute Myo-
ardial Infarction) was a multicenter randomized controlled
linical trial that evaluated the effectiveness of hypothermia
n reducing myocardial infarct size (74). In this trial of 357
atients, 177 patients were randomized to receive an endo-
ascular cooling catheter (Reprieve, Radiant Medical, Red-
ood City, California) positioned in the inferior vena cava
hrough the femoral vein. When the patients arrived in the
atheterization laboratory, hypothermia was induced by
irculating cooled saline through the device, thereby cooling
he blood as it passed along the catheter. Although this study
ailed to show an overall difference in infarct size, the investi-
ators did notice a trend toward smaller infarctions in patients
eceiving hypothermia who had anterior MIs versus those with
nferior MIs. Further investigation showed that patients with
nterior MIs who were cooled to temperatures 35°C before (eperfusion had significantly smaller infarctions than controls
9.3% in treated patients vs. 18.2% in controls; p 0.05), albeit
n a small number of patients (n  16).
A major limitation to COOL-MI was that only a
inority of patients was able to reach the target temperature
f 35°C before reperfusion—likely due to the rapid
oor-to-balloon time and a slow cooling process. The
APID-MI-ICE (Rapid Intravascular Cooling in Myocar-
ial Infarction as Adjunctive to Percutaneous Coronary
ntervention) trial was designed to evaluate the safety and
easibility of rapidly induced hypothermia before reperfu-
ion (75). Twenty patients were randomly assigned to
ypothermia or control. In addition to an endovascular
ooling catheter, patients in the hypothermia group received
n intravascular infusion of 1 to 2 liters of cooled saline. All
atients in the hypothermia group attained a core body
emperature of 35°C before reperfusion without a signif-
cant delay in door-to-balloon time. Rapidly induced hypo-
hermia was found to reduce infarct size normalized to area
t risk by 38% compared with controls (29.8  12.6% in
reated patients vs. 48.0  21.6% in controls; p  0.04), as
ssessed by cardiac MRI performed 4  2 days following
I. Additionally, no increase in adverse events was seen.
his pilot study demonstrated that attaining a core body
emperature of 35°C may be effective in reducing myo-
ardial infarct size and can be quickly and safely induced
ithout a significant delay in reperfusion or increase in
dverse events.
upersaturated oxygen therapy: AMIHOT I and II. Al-
hough still somewhat controversial, lethal reperfusion in-
ury may play an important role in myocardial ischemia-
eperfusion injury (76,77). Although complex and
amaging, reperfusion injury provides an attractive target
or adjunctive cardioprotection therapy because, unlike the
nitial ischemic event, the moment of reperfusion can
sually be controlled.
An adjunctive therapy that may attenuate reperfusion
njury is hyperoxemic therapy, and a recently published
ivotal trial demonstrated this approach to be effective.
MIHOT II (Acute Myocardial Infarction With Hyper-
xemic Therapy II) was a prospective multicenter study of
01 patients with anterior STEMI who presented within
h of symptom onset (78). Patients were randomized to
eceive a 90-min intracoronary infusion of supersaturated
xygen immediately following PCI or standard of care
herapy. This trial was designed following the disappointing
esults of AMIHOT I, which evaluated hyperoxemic ther-
py in patients with anterior or large inferior MIs presenting
ithin 24 h of symptom onset (79). AMIHOT I failed to
eet its primary efficacy endpoints of change in wall motion
everity index at 3 months, ST-segment curve area 3 h after
CI, and final infarct size at 14 to 21 days. However, post
oc analysis indicated a possible benefit in patients with
nterior MIs presenting within 6 h of symptom onset.
AMIHOT II indeed demonstrated positive results
78). Using Bayesian hierarchical modeling, the research-
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March 13, 2012:969–78 Update on Cardioprotectioners were able to borrow evidence from patients enrolled in
AMIHOT I that met inclusion criteria for AMIHOT II.
This underused yet well-established technique allows for a
smaller sample size and therefore more rapid completion of
pivotal clinical trials (80). When data from AMIHOT I and
II were pooled, infarct size was found to be significantly
reduced (25% [IQR: 7% to 42%] in the control group vs.
18.5% [IQR: 3.5% to 34.5%] in the treated group; PWilcoxon 
.02; Bayesian posterior probability of superiority 96.9%).
dditionally, in patients with a baseline LV ejection frac-
ion of 40%, infarct size was reduced from 33.5% in
ontrols to 23.5% in the treatment group. This incremental
yocardial salvage of 10% is even better than the 6.5%
alvage seen in the entire study population, indicating that
his therapy may be most beneficial in patients with more
evastating infarctions.
romising Therapies for the Future
itrates. There is a renewed interest in nitrates as a
ardioprotectant in recent years because new clinical and
nimal model studies have shown promising results. Early
linical trials in the pre-thrombolytic era of the 1970s and
980s suggested that nitrates could reduce mortality in the
etting of AMI, and a large meta-analysis published in the
ancet in 1988 confirmed this mortality benefit (81). How-
ver, 2 large clinical trials, GISSI-3 (Gruppo Italiano per lo
tudio della Sopravvivenza nell’Infarto Miocardico 3) (82)
nd ISIS-4 (Fourth International Study of Infarct Survival)
83), were designed to address the possible mortality benefit
f nitrates in the setting of AMI with thrombolytic therapy,
nd both trials failed to show a benefit.
More recently, several clinical studies have shown the
otential of nitrates to limit myocardial infarct size. Am-
rosio et al. (84) retrospectively analyzed the GRACE
Global Registry of Acute Coronary Syndromes) data set to
etermine if antecedent nitrate therapy led to less myocar-
ial necrosis during the ischemic event. The researchers
ound that 18% of chronic nitrate users were diagnosed with
TEMI compared with 41% of nitrate-naive patients.
ikewise, 82% of nitrate users presented with non–STEMI
ompared with 59% of patients who were nitrate naive.
hey also found that antecedent nitrate use was associated
ith lower CK-MB and troponin levels, regardless of acute
oronary syndrome type.
Nitroglycerin has also been shown to have pre-
onditioning mimetic action in several clinical circum-
tances. In patients with stable angina, pre-treatment with
ntravenous nitroglycerin 24 h before an exercise tolerance
est improved functional capacity and electrocardiographic
anifestations of ischemia exhibited by a decrease in max-
mal ST-segment depression, total sum of ST-segment
epression, and time to resolution of ST-segment depres-
ion (85).
The same investigators also showed that nitroglycerin can
ave cardioprotective effects when given 24 h before coro-ary angioplasty. Patients who received nitroglycerin had
mprovement in ST-segment shifts, regional wall motion
bnormalities, and chest pain scores after balloon inflation
ompared with patients who received saline (86).
hosphodiesterase-5 inhibitors. Currently, there are 3
hosphodiesterase isoform 5 (PDE5) inhibitors available for
he treatment of erectile dysfunction: sildenafil, vardenafil,
nd tadalafil. In the past several years, there has been
onsiderable attention paid to their potential cardioprotec-
ive properties, and indeed, there is a growing body of pre-
linical evidence to support it. The mechanism of PDE5
ardioprotection is complex and beyond the scope of this
eview, but PDE5 inhibitors appear to be ischemic pre-
onditioning mimetics (87–89) as well as inhibitors of
PTP formation (90). Other mechanisms may involve
eduction in arterial blood pressure (91), attenuation of
notropic responses to catecholamines (92,93), and nitric
xide signaling (94,95).
onclusions and Future Perspectives
he last 3 decades have seen hundreds of potentially
ardioprotective adjunctive therapies come and go with
one becoming commonplace in clinical practice. The
easons for these translational failures have been discussed at
ength and well documented in published reports (17).
everal therapies, however, have now proven beneficial in
linical trials, and although more studies are needed, we are
ndeed getting closer to a safe and effective adjunct to
eperfusion. Interestingly, candidate treatments with the
ost potential involve many different treatment modalities,
nd pre-clinical investigators must use multiple laboratories
nd animal models to increase the likelihood of bringing a
uccessful therapy to clinical trial.
Although rapid reperfusion of ischemic myocardium
emains the standard of care for AMI, we must strive to
educe the amount of cell death even further. With the help
f initiatives such as CAESAR and other multilaboratory
fforts (106), future large-scale clinical trials will determine
hich therapy or combination of therapies will be most
fficacious in reaching this ambitious yet attainable goal.
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